What Is Cartalax?

1. What is Cartalax, and where did it come from?

PubChem’s compound record lists Cartalax and “T-31 peptide” as synonyms for the same small molecule. In research papers it usually appears as AED, the one-letter codes for its three amino acids.

According to a 2023 review from the Khavinson group, AED is one of several short peptides identified in a polypeptide complex extracted from animal cartilage. The review reports that this cartilage extract, not AED itself, entered phase 2 trials for osteoarthritis in Russia. A related cartilage-and-bone extract, Sigumir, is discussed alongside AED in the group’s Russian-language review of chondrocyte aging.

Cartalax sits in the same family as Epitalon, Pinealon and Thymalin, each promoted by the same group for a particular tissue. Cartalax’s three amino acids are the same as the first three of Epitalon’s four, but the two are different molecules. A result reported for one cannot be borrowed for the other.

2. How is Cartalax supposed to work?

The Khavinson group proposes that short peptides pass through cell and nuclear membranes and attach directly to DNA, turning particular genes up or down. For AED, this rests on computer docking, a simulation that predicts how two molecules might fit together. In Khavinson and colleagues’ 2016 paper, the model predicted that AED binds a specific short stretch of DNA, while the authors acknowledged that the molecular mechanism remained unclear.

A docking prediction is a hypothesis about binding, not a measurement inside living cells. No study has shown that AED reaches cartilage after being swallowed or injected, or that it binds DNA in a person. The general peptide guide explains why a very short peptide taken by mouth faces digestion before it can act anywhere.

3. What do the cartilage and stem-cell studies show?

These are laboratory experiments on cells grown in dishes. They show what AED changed in a culture, not whether joints feel or work better.

The concentrations above are amounts in a culture dish. They say nothing about how much would reach a knee joint in a person, or whether that would be possible at all.

Other cell studies: skin, kidney and thymus

The group has also applied AED to non-cartilage cells. In aging human skin fibroblasts, the cells that make collagen, Fridman and colleagues reported higher sirtuin-1, sirtuin-6 and type I collagen. An earlier fibroblast study reported lower MMP-9, an enzyme that breaks down tissue, and less programmed cell death.

In kidney cell cultures, AED was reported to increase cell division and lower the aging markers p16, p21 and p53 (Khavinson et al., 2014). In rat kidney tissue cultures, it supported cell renewal but less strongly than the calf-kidney extract it was compared with (Chalisova et al., 2015).

Not every comparison favored AED. In aging thymus cell cultures, Lin’kova and colleagues tested T-31 alongside two other peptides, and only one of the others produced the full set of effects the authors were looking for.

4. What did the animal studies find?

Three rat studies with AED have been published. None is an osteoarthritis model with reported numbers, despite the review’s statement that AED worked in such models.

The abstracts do not give doses, routes or group sizes. A recurring pattern is that AED did something, but the tissue extract or another peptide did more. Rat bone density after ovary removal is also a different question from cartilage repair in an arthritic human knee.

5. Is there any human evidence for joints or osteoarthritis?

No randomized or controlled trial of AED in people has been published. The only human claim appears in the 2023 Russian-language review, which states that Sigumir and AED showed high efficacy with oral use in older patients with osteoarthritis.

That sentence comes without a patient count, dose, treatment length, comparison group or outcome measure, and no underlying study could be located. A claim in that form cannot be evaluated, so it should not be read as evidence that Cartalax eases joint pain or rebuilds cartilage.

Every cell and animal study described above also involves Khavinson or his institute’s staff. No independent laboratory has published a replication. That does not make the findings false, but it leaves them unconfirmed.

6. Is Cartalax legal or FDA approved?

Cartalax is not an approved drug in the US, and no FDA or EMA approval for any AED product could be found. It was also not named on FDA’s list of bulk substances that may pose significant safety risks in compounding when checked, although Epitalon is named there. Absence from that list does not mean FDA reviewed Cartalax or considers it safe.

For athletes, AED is not named on the 2026 WADA Prohibited List. The list’s S0 class bans, in and out of competition, pharmacological substances that lack approval from any government health authority for human therapeutic use. No AED-specific WADA ruling was found, so tested athletes should treat it as a risk.

7. Cartalax dosage and half-life: what is known?

There is no established human dose. The papers are cell and rat studies, and the one human claim gives no dose. Concentrations used in a culture dish cannot be converted into an amount to swallow or inject.

Half-life is also unknown. No published study has measured how AED is absorbed, where it goes, how long it lasts or how it is cleared, in people or animals. A half-life tool can only model a curve from an assumed number; for Cartalax there is no measured number to start from.

8. Side effects, interactions and GLP-1 medicines

AED’s safety in people has never been systematically studied. No acute, repeat-dose, reproductive or genetic toxicology studies have been reported, and nothing is known about use in pregnancy, breastfeeding, children, or kidney, liver or autoimmune disease. Because none of the group’s papers was designed to detect harm, a lack of reported side effects is not evidence of safety.

Product quality is a separate risk. Cartalax sold online is unregulated in the US, so identity, purity, amount per capsule or vial, and sterility of injectable forms are not independently verified. FDA has flagged immune reactions from impurities and aggregates as a concern for similar research peptides such as Epitalon, according to its compounding safety-risk page.

The group’s own stem-cell data add a caution. AED raised expression of NF-κB, a central switch for inflammation, and IGF1, which promotes cell growth (Ashapkin et al., 2020). Whether those changes would help, harm or not matter in a living person has not been studied.

Using Cartalax alongside semaglutide or tirzepatide

No study has tested AED with semaglutide, tirzepatide or any other medicine, and no interaction data exist. None of the studies measured muscle, bone or joint outcomes during weight loss, so they offer no support for using Cartalax to offset the changes discussed in the GLP-1 and muscle loss guide. For bone, teriparatide is an example of a peptide with an FDA approval and human trial data.

9. What can you meaningfully track?

No blood test or scan can confirm that AED reached cartilage or changed gene activity. What a person can record are everyday outcomes: joint pain on a consistent scale, stiffness in the morning, walking distance or a repeatable activity, and any new symptoms or reactions.

Those records cannot show cause. Joint pain naturally rises and falls, and changes in weight, activity, footwear, pain relievers or other supplements can all shift it. If several products start at once, a log cannot tell which one mattered.

A clear record of product names, dates, symptoms and other changes is most useful as something to bring to a clinician. The peptide tracking guide covers ways to keep those details together. The result that would actually change the picture for Cartalax is an independent, controlled human trial with a defined product, joint outcomes and safety follow-up.

10. Cartalax FAQ

• Is Cartalax legal?

  Cartalax is not an FDA-approved drug, and no FDA or EMA approval was found. Products sold online are unregulated in the US, so their contents and purity are not independently verified. Laws on buying or importing unapproved substances vary by country.

• Does Cartalax help joint pain or osteoarthritis?

  That has not been shown. No controlled human trial has been published. A 2023 Russian review says AED was effective in older people with osteoarthritis but gives no patient numbers, doses, comparison group or results, so the claim cannot be checked.

• What are the side effects of Cartalax?

  They are unknown. No study has systematically measured AED's safety in people, and no toxicology studies have been reported. The lack of reported side effects reflects the lack of human research, not proof of safety.

• How long does Cartalax stay in your system?

  No one knows. No study has measured AED's absorption, distribution, half-life or excretion in people or animals. Half-life figures that circulate online are not based on published measurements.

• Can Cartalax be used with semaglutide or tirzepatide?

  No study has tested AED alongside semaglutide, tirzepatide or any other medicine, and no interaction data exist. Anyone considering an unapproved peptide while on a prescription GLP-1 should discuss it with their prescriber.

• Is Cartalax the same as Epitalon?

  No. Both come from the Khavinson group, and Cartalax's three amino acids match the first three of Epitalon's four, but they are separate molecules with separate research. Results for one do not transfer to the other.

• What is the dose of Cartalax?

  There is no established human dose. The published papers are cell and rat experiments, and the one human claim does not state a dose. Laboratory concentrations cannot be converted into a personal dose.

• Is Cartalax banned in sport?

  AED is not named on the 2026 WADA Prohibited List. However, WADA's S0 class bans at all times any substance without government approval for human therapeutic use, and no WADA ruling specific to AED was found.

11. Sources